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Abstract - Dopamine is still frequently used as a first line 
vasopressor agent in hypotensive patients, when physicians 
are afraid of noradrenaline and believe that dopamine, with 
its  β and α,  inotrope and vasopressor effects, may be helpful. 
Evidence exists that it does not offer protection from renal 
failure, even if at low doses (0, 3-5 mcg/Kg/min) it may exert 
its effects on D1 and D2 receptors resulting in natriuresis and 
renal vasodilation, augmentation in renal blood flow, and 
diuresis.  
The effects of dopamine on gastrointestinal system and 
splanchnic perfusion in critical care patients are even more 
controversial, since they seem to be at least partially 
dependent on the initial fractional splanchnic blood flow. 
Dopamine may exert deleterious effects on respiratory 
function, by impairing the ventilatory drive response to 
hypoxemia and hypercapnia and reducing arterial oxygen 
saturation through a regional ventilation/perfusion 
mismatching. Dopamine seems to affect the cellular mediated 
mechanism of the immune function directly by its action on 
receptors located on immune system cells and indirectly 
altering the hormonal response regulating immune response. 
In this paper, the use of low dose dopamine is discussed in the 
intensive care perspective. 
 





Dopamine (DA) remains an essential drug in Intensive 
Care Units (ICU), where it is still used as a first line 
vasopressor agent in hypotensive patients, refractory to 
fluid resuscitation, because of the feared ischemic side-
effects of norepinephrine on end-organ perfusion.  
Nevertheless, the results of the SOAP study showed 
that dopamine administration in shock patients, compared 
to patients who did not receive it, was associated with 20 
% increase in ICU and hospital mortality rates [1]. 
Alternatives to dopamine infusion exist, as noradrenaline 
i.e. or other vasopressors, and informed guideline for 
sepsis management are available worldwide even if with 
some concerns are raised [2, 3].  
Pharmacology of dopamine is interesting: its peculiar 
spectrum of action resides in the dose dependent 
interaction to different catecholamine receptors.  
At low doses (0.3-5 μg/Kg/min) DA exerts its effects 
on D1 and D2 receptors resulting in, as the kidney is 
concerned, natriuresis and renal vasodilation, augmentation 
in renal blood flow, and diuresis.  
Dose dependent interactions on different receptors are 
not a clear cut-off value but represent the prevalence of 
activation of a group of receptors over another with a wide 
range of inter-individual variability. Thus, even a low 
dosage of dopamine may exert a systemic vasocostrictory 
action without relevant improvement in renal function [4]. 
A low dosage of dopamine may even jeopardize mucosal 
blood flow in the gut, suppress the function of the pituitary 
gland, interfere with cell mediated immunity and impair 
the thyroid function [5-7]. 
The optimal selection of dopamine dosages is far less 
clear in critical care settings where an altered receptor 




II. RENAL EFFECTS 
 
The era of dopamine, particularly “low dose 
dopamine” (LDD), began in 60’s when Goldberg described 
its effects on four patients affected by end stage congestive 
heart failure [8]. Drug administration, in doses ranging 
from 100 to 1,000 mcg/min, increased cardiac output and 
sodium urinary excretion. This phenomenon occurred at 
lower doses, and with minimal impact on cardiovascular 
status. 
The same investigators showed that dopamine 
administration was able to increase plasmatic flow in the 
kidney, glomerular filtration, and sodium excretion in 
healthy human subjects [9]. In this study, the dose 
administered was titrated to achieve maximal renal effect 
without increasing mean arterial pressure. 
In 1965, the same authors investigated the renal effects 
of dopamine in anaesthetised dogs and concluded that 
dopamine might exert its action on particular receptors 
located in the kidneys [10]. Twenty years after research by 
D’Orio et al., a series of dose response curves, based on 
renal and haemodynamic effects observed in patients to 
whom different doses of dopamine were administered, 
were observed [11].  
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The dopamine suppressor dose was at that time 
defined as the dose at which dopaminergic and possibly 
adrenergic stimulation prevailed over adrenergic 
stimulation. This threshold corresponded to the infusion 
rate: < 5g/kg/min [11].  
Dopamine exerts its effects on the kidneys in dose 
dependent fashion.  
At low doses, such as 0.3-5 μg/Kg/min, dopamine acts 
on D1 vascular receptors, which in turn increases renal 
blood flow. It appears that dopamine may additionally 
interact with D2 receptors located on presynaptic nerve 
endings, inhibiting the release of norepinephrine [12]. At 
higher doses, when adrenergic stimulation prevails, renal 
blood flow is augmented by the increase in cardiac output. 
Dopamine is able to induce diuresis and natriuresis by 
acting on both D1 and D2 receptors located on the 
proximal tubule, which is the thick ascending loop of the 
Henle and cortical collecting tubule.  





adenosine triphosphatase activity. In fact, it appears that 
the primary effect on renal epithelial cells is the removal of 




 ATPase units. The 
net effect is the reduced capability of the tubular cells to 
Na
+
 transport [13].  
Moreover, the stimulation of D2 receptors located on 
the collecting tubules of the inner medulla stimulates 
production of prostaglandin E2, (PGE2), which 
counterbalances the effects of antidiuretic hormones, 
augmenting the clearance of free water [14, 15].  
The renal vasodilatory effects are associated with 
dose-dependent augmentation in renal blood flow and 
diuresis.  
LDD induces a redistribution of intraparenchymal 
renal blood flow towards the cortical region, counteracting 
the effect of PGE2 and shunting blood away from the outer 
medulla [16]. 
This can be harmful for two reasons. First, renal 
medulla has a limited blood supply. Second, it may 
promote a relative ischemia in a region that is high 
metabolically active and already works with a lower 
tension of oxygen. 
In fact, although the kidneys receive nearly 20 per cent 
of cardiac output, the greatest part of the blood flow 
supplies the outer parenchymal layers [17]. 
For years LDD was a widely accepted therapeutic 
option to limit or prevent acute renal failure in critical care 
patients, especially those affected by sepsis. Even if largely 
studied, sepsis is still the greatest danger for these patients’ 
life, with many obscure sides on its presentation, causes 
and prevention possibilities [18, 19]. Several investigations 
were carried out to assess the effects of LDD on renal 
function in critical patients who were at risk or had 
established renal failure. 
In some studies, LDD administration increased urine 
output; however, in others, no effect was found [11, 20-
23]. 
One study showed a potential negative effect of LDD 
dopamine administration on tubular function caused by the 
augmented urinary excretion of retinol binding protein in 
patients who had undergone coronary bypass surgery [22]. 
Another paper showed that in post-cardiac surgery, 
patients with normal preoperative renal function, dopamine 
was reported to increase renal oxygenation without 
increasing glomerular filtration rate, tubular sodium 
reabsorption, or renal oxygen consumption [24].  
In fact, there is convincing evidence from literature 
that LDD not only is unable to prevent, reverse, or limit the 
progression of acute renal failure (ARF), but its use, 
regardless of a clear assessment of the volemic status of 
the patients, may increase the risk of ARF.  
Moreover, a large prospective randomized study by the 
Australian and New Zealand Intensive Care Society Group 
showed that LDD not only was unable to prevent or 
reverse acute renal failure, but it failed to improve outcome 
variables. 
In fact, there were no differences in terms of mortality, 
need of renal replacement therapy, renal recovery, and 
peak serum creatinine among the patients. 
These findings confirmed the results of the 
retrospective analysis of the North American Septic Shock 
Trial (NORASEPT), where no reduction of the incidence 
of acute renal failure, the 28-day mortality, nor the 
requirement of haemodialysis were observed in septic 
patients who developed oliguria [25]. 
In two recent meta-analyses about the impacts of LDD 
on ARF, the first by Kellum and Decker, dopamine did not 
prevent mortality, the onset of acute renal failure, or the 
need for haemodialysis [26]. The second, by Marik, 
analysed 15 randomised controlled studies by comparing 
LDD administration with a placebo; there were no 
beneficial results in terms of serum creatinine change and 
incidence of acute renal failure [27].  
It has been argued by some authors that adding LDD 
in patients requiring norepinephrine may limit its adverse 
effects on renal circulation and function. 
Clear beneficial evidence on renal function of this 
therapeutic regime is lacking, as shown by studies carried 
out on experimental animal models and in patients with 
septic shock who require catecholamine administration. 
It seems clear that LDD mediated increases in urinary 
output in septic shock patients treated with norepinephrine 
are probably mediated by the augmentation of cardiac 
output. 
Recent evidence has shown that norepinephrine 
administration can effectively restore an adequate 
hemodynamic status in adequately fluid resuscitated 
patients [28]. 
The use of norepinephrine has been shown to have a 
protective effect on renal blood flow and to increase 
diuresis in animal and human septic shock conditions. 
A low dosage dopamine appears to be able to increase 
in urinary output in critically ill patients, but it doesn’t play 
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any protective role against acute renal failure and does not 
improve the course of an established acute renal failure. 
When administered to critical patients, it may increase 
the risk of acute renal failure. 
It could be interesting, but far from the topic of this 
review, to consider the use of new molecules in 
combination with dopamine, as vaptans i.e [29].  
 
 
III. GUT AND MESENTERIC EFFECTS 
 
Gut has been considered as the “motor” of systemic 
inflammatory response syndrome (SIRS) [30]. In fact, 
alterations of mesenteric blood flow and gut hypoperfusion 
represent the first response to hemodynamic derangements 
in critically ill patients when blood, pooled away from 
intestinal viscera, is redistributed to “vital” organs. This 
response causes intestinal hypoperfusion that facilitates the 
alteration of the barrier function and the increase of 
intestinal epithelial apopotosis [31]. 
In experimental models, dopamine increased both 
splanchnic ad hepatic blood flow. In a study on dogs, 
dopamine reduced intestinal blood flow, and in a porcine 
model, it seemed to hasten gut ischemia. 
Those results seem to be due to the ability of DA to 
reduce blood flow to the mucosa by redistributing it within 
the gut. 
In another animal study DA improved mucosal blood 
flow and oxygenation [32]. 
Data regarding human studies shared the same deal of 
equivocal conclusion.  
In fact, some investigations showed that LDD can 
increase splanchnic blood flow in septic cardiac surgical 
patients, whereas others did not draw the same results [33-
35]. 
LDD seemed to decrease splanchnic oxygen 
consumption in septic patients in spite of an increase in 
splanchnic blood flow, and once again this effect was not 
confirmed in cardiac surgical patients.  
LDD increased oxygen transport in septic patients but 
led to a diminished gastric mucosal flow and did not affect 
pHi, a common and widely accepted marker of gut 
mucosal perfusion. 
The effect of DA administration seems to be at least 
partially dependent on the initial fractional splanchnic 
blood. 
Recently, De Backer et al. found no differences in 
PCO2 gap, splanchnic blood flow in their study, which was 
carried out on 20 septic patients. Moreover, dopamine 
administration showed a lower mixed venous-hepatic 
venous saturation gradient.  
DA 2 receptors are present in human enteric nervous 
endings, and dopamine administration may actually affect 
gastrointestinal motility. 
These effects have been confirmed both in healthy 
subjects who had undergone short-term DA administration, 
and in critically ill patients, in doses ranging from 2.5 to 5 
μg/kg/min. Moreover, in another paper, LDD impaired 
gastroduodenal emptying in mechanically ventilated 
patient during fasting and nasogastric enteral feeding [36]. 
Moreover there are data suggesting that norepinephrine 
does not impair splanchnic circulation in animal models of 
endotoxin shock and in septic patients. On the contrary, 
norepinephrine was associated with a greater increase in 
pHi as compared to dopamine in septic shock patients. 
Again, dopamine (4μg/kg/min) reduced hepatosplanchnic 
oxygen uptake in spite of an increase in systemic and 




IV. RESPIRATORY EFFECTS 
 
Intensive care patients are very often mechanically 
ventilated being respiratory failure the cause of their 
recovery in ICU or a complication of their illness [37-40]. 
As pointed out, DA administration may exert deleterious 
effects on respiratory functions. It impairs the ventilatory 
drive response to hypoxemia and hypercapnia by 
depressing the carotid body. It further reduces arterial 
oxygen saturation through a regional ventilation/perfusion 
mismatching. This does not represent a problem as long as 
patients are mechanically ventilated and an oxygen 
supplement is administered.  
Problems can arise during the weaning process from 
ventilatory support, when the physiological response to 
both hypoxia and hypercapnia might have been blunted by 
DA administration. LDD may favour weaning from the 
ventilator, but this comes at the expense of an actual risk of 
hastening respiratory failure. 
 
 
V. ENDOCRINE AND IMMUNOLOGICAL 
EFFECTS 
 
Low doses of dopamine result in plasmatic levels up to 
100 times higher than those generated by endogenous 
secretions, which may cause partial hypopituitarism in 
adults, infants, and children. In a work by Van den Berghe 
[41] on 12 polytrauma patients, LDD dopamine 
administration lowered levels of thyroid stimulating 
hormones, thyroxine, and triiodothyronine. All values 
came back to normal after 24 hours from the suspension of 
DA. 
LDD infusion may trigger or exacerbate the euthyroid 
sick syndrome in critical illnesses. 
DA administration affected the secretion of the growth 
hormone (GH) in critically ill patients as pointed out by the 
same authors. GH pulsatile secretion is impaired in 
critically ill patients and it resulted further by being 
blunted by DA administration. The authors concluded that 
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the suppression of GH secretion might enhance the 
catabolic process of critical illnesses.  
LDD dopamine has been show to suppress 
dehydroepiandrosterone (DHEAS) and prolactine levels in 
20 critically ill patients [41]. 
Cortisol levels were not affected. The levels of 
luteinizing hormone (LH) and testosterone were affected 
by dopamine administration in 15 critically ill men. 
LH rose after three hours from dopamine withdrawal, 
while testosterone levels failed to rebound. 
Dopamine receptors have been discovered on 
thymocytes, and dopamine is able to interact with 
lymphocytes. Dopaminergic agonist and dopamine 
suppress T- lymphocytes function and suppress T-cell 
functions in mice. In humans, specifically critically ill 
patients receiving dopamine, the drug was able to reduce 
the T-cells’ responsiveness  
Prolactine, whose levels have been shown to decrease 
under dopamine infusion, has immunoregolatory functions; 
B and T types have indeed prolactine receptors. 
The reduction of DHEAS has been advocated as a 
further cause of immune cellular response, because of 
lymphocyte T-helper and type 1-T lymphocyte induced 
dysfunction. 
Dopamine seems to affect the cellular mediated 
mechanism of the immune function directly by its action 
on receptors located on immune system cells and indirectly 






Dopamine “owes” its popularity to the work of 
Goldberg. Over the years, renal and splanchnic protective 
effects have been challenged and not confirmed at all. 
There is no equivocal conclusion about its effects on gut, 
but DA has been proven to cause major disturbances in 
anterior pituitary function and the immune system and may 
further impair muscular blood supply.  
We can conclude that low dose dopamine for renal 
protection is no longer justified and should be definitely 
abandoned. Its use as a first choice vasopressor should be 
questioned in view of its potentially deleterious side effects 
and the increased rate of mortality associated with its 
administration in septic patients. However, DA is still used 
by medical personnel; many doctors are familiar with the 
medication and feel comfortable for its application, 
therefore, it becomes part of their routine treatment: in 
clinical situations, very often, the choice of catecholamine 
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